ERBB2 and breast carcinoma: A trial (Capello-291, NCT04305496) assessed the efficacy of capivasertib in combination with fulvestrant in patients with inoperable or metastatic HR-positive and HER2-negative breast cancer, including those with PIK3CA/AKT1/PTEN alterations.